Firas El Chaer, MD, University of Virginia, Charlottesville, VA, shares the results of a real-world analysis comparing the use of standard-dose anthracycline vs high-dose anthracycline vs anthracycline plus gemtuzumab ozogamicin in patients with favorable risk acute myeloid leukemia (AML).